We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen, Wyeth and several other companies are facing a lawsuit over allegations that they engaged in off-label marketing of the erythropoiesis-stimulating agents (ESAs) Aranesp and Enbrel.